Effect of Dapagliflozin on Volume of Epicardial Adipose Tissue in Asymptomatic Heart Failure - DAPA-EAT

Tanaka Atsushi0 个研究点目标入组 230 人开始时间: 2022年5月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients are aged 20 years or older.
•2. Patients have consented to participate in the study and understand the procedures of the study.
•3. Patients with asymptomatic heart failure (NYHAclass I).
•4. Patients who are receiving at least one standardtherapy for heart failure (ACEI/ARB, MRA, or betablockr)
•and have not changed the dose of the therapy within 2 weeks prior to enrollment.

•1. Patients with a history of taking SGLT2 inhibitors.
•2. Patients with a history of hypersensitivity to any component of Dapagliflozin.
•3. Patients with type 1 diabetes mellitus.
•4. Patients with significant anemia (hemoglobin less than 9g/dL).
•5. Patients with serum AST/ALT/ALP levels exceeding the specified values (AST >150IU/L, ALT >150I
•U/L, ALP >300U/L).
•6. Patients with severe renal failure (eGFR less than 30ml/min/1.73m2).
•7. Patients receiving systemic administration of steroids. Topical administration of steroids (application, local injection, inhalation, etc.) is acceptable.
•8. Patients with a history of alcohol or drug abusewithin 3 months.
•9. Patients with urinary tract/genital tract infections within 2 weeks.
•10. Patients with severe aortic stenosis.
•11. Patients with symptomatic coronary artery disease.
•12. Patients scheduled to undergo cardiovascularsurgery within 24 weeks of enrollment.
•13. Patients with systolic blood pressure of less than 90 mmHg.
•14. Patients who are allergic to contrast media and cannot undergo contrast-enhanced CT.
•15. Women who are pregnant, lactating, or who wish (or plan) to become pregnant.
•16. Patients who are otherwise judged by the principal investigator or sub-investigator to be inappropriate for participation in the study.

发起方

Tanaka Atsushi